Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Alzheimer's Disease

Free Subscription Articles published in Lancet Neurol Retrieve available abstracts of 66 articles: HTML format

Single Articles

October 2026
1. GRAFF-RADFORD J, Karliner L, Barnes DE, Frisoni GB, et al
   Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change.
   Lancet Neurol. 2026;25:952-964.
   PubMed     Abstract available
   
   
   
2. BENZINGER TLS, Cogswell PM, Arani A, Chaney AM, et al
   Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy.
   Lancet Neurol. 2026;25:939-951.
   PubMed     Abstract available
   
   
   
3. TEUNISSEN CE, Vermunt L, Barthelemy NR, Benzinger TLS, et al
   Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders.
   Lancet Neurol. 2026;25:926-938.
   PubMed     Abstract available
   
   
   
4. LAN G, Guo T
   Charting the future of biomarkers and therapy in Alzheimer's disease.
   Lancet Neurol. 2026;25:879-880.
   PubMed    
   
   
   
5. THE LANCET NEUROLOGY
   Alzheimer's disease testing needs evidence, ethics, and equity.
   Lancet Neurol. 2026;25:873.
   PubMed    
   
   
   September 2026
6. MU R, Hofmann A, Gong K, Liu M, et al
   Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study.
   Lancet Neurol. 2026 Sep 24:S1474-4422(26)00284.
   PubMed     Abstract available
   
   
   June 2026
7. PATEL M, Feng W, Mckay NS, Millar PR, et al
   Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study.
   Lancet Neurol. 2026;25:581-590.
   PubMed     Abstract available
   
   
   
8. KOSIK KS
   Genetic modifiers in autosomal dominant Alzheimer's disease.
   Lancet Neurol. 2026;25:537-538.
   PubMed    
   
   
   April 2026
9. MATTSSON-CARLGREN N, Palmqvist S, Horie K, Barthelemy N, et al
   Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease: a prospective cohort study.
   Lancet Neurol. 2026;25:357-367.
   PubMed     Abstract available
   
   
   
10. ASHTON NJ
    Biologically informed blood testing in Alzheimer's disease.
    Lancet Neurol. 2026;25:327-329.
    PubMed    
    
    
    March 2026
11. REIMAN EM, Alexander RC, Langbaum JB, Aisen PS, et al
    A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA.
    Lancet Neurol. 2026;25:268-278.
    PubMed     Abstract available
    
    
    
12. SCHNEIDER L
    When Alzheimer's disease prevention becomes policy: regulatory speed, commercialisation, and risk.
    Lancet Neurol. 2026;25:219-220.
    PubMed    
    
    
    
13. THE LANCET NEUROLOGY
    Stopping Alzheimer's disease before symptoms start.
    Lancet Neurol. 2026;25:213.
    PubMed    
    
    
    February 2026
14. TARIOT PN, Lopera FS, Rios-Romenets S, Sink KM, et al
    Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1(Glu280Ala) mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled tri
    Lancet Neurol. 2026;25:147-159.
    PubMed     Abstract available
    
    
    
15. FORTEA J, Llibre-Guerra J, O'Connor A, Levin J, et al
    Lessons from the Colombian kindred: rethinking Alzheimer's prevention.
    Lancet Neurol. 2026;25:117-119.
    PubMed    
    
    
    January 2026
16. VOSSEL K, Johnson EL, Cretin B, Matsumoto R, et al
    Epileptic activity in Alzheimer's disease: emerging insights and therapeutic implications.
    Lancet Neurol. 2026 Jan 22:S1474-4422(25)00425.
    PubMed     Abstract available
    
    
    
17. DEVINSKY O
    Alzheimer's disease and epileptic activity: uncertainties abound.
    Lancet Neurol. 2026 Jan 22:S1474-4422(25)00496.
    PubMed    
    
    
    
18. MORGAN J
    Takeshi Iwatsubo: a pioneer in Alzheimer's disease research.
    Lancet Neurol. 2026;25:33.
    PubMed    
    
    
    December 2025
19. RABINOVICI GD
    Progress in Alzheimer's disease: The Lancet Series.
    Lancet Neurol. 2025;24:991-992.
    PubMed    
    
    
    
20. SCHOLZ SW, Okubadejo NU, Prakash P, Liddelow SA, et al
    Advances in the genetics and pathology of Lewy body dementia.
    Lancet Neurol. 2025;24:1026-1037.
    PubMed     Abstract available
    
    
    
21. JACK CR JR, Hu M, Wiste HJ, Knopman DS, et al
    Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study.
    Lancet Neurol. 2025;24:1016-1025.
    PubMed     Abstract available
    
    
    November 2025
22. BOON BDC, Piura YD, Moloney CM, Chalk JL, et al
    Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study.
    Lancet Neurol. 2025;24:931-944.
    PubMed     Abstract available
    
    
    
23. IWATSUBO T
    Neuropathology of Alzheimer's disease after anti-amyloid beta antibody treatment.
    Lancet Neurol. 2025;24:897-899.
    PubMed    
    
    
    September 2025
24. RAFII MS, Schlachetzki Z, Barroeta I, Head E, et al
    Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology.
    Lancet Neurol. 2025;24:753-762.
    PubMed     Abstract available
    
    
    
25. THERRIAULT J, Brum WS, Trudel L, Macedo AC, et al
    Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Lancet Neurol. 2025;24:740-752.
    PubMed     Abstract available
    
    
    
26. RYAN NS
    Alzheimer's disease in Down syndrome: progress and promise.
    Lancet Neurol. 2025;24:717-718.
    PubMed    
    
    
    
27. KESHAVAN A, Algeciras-Schimnich A
    Plasma phosphorylated tau for Alzheimer's disease diagnosis.
    Lancet Neurol. 2025;24:715-717.
    PubMed    
    
    
    August 2025
28. LI Y, Llibre-Guerra JJ, Supnet C, Atri A, et al
    Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease - Authors' reply.
    Lancet Neurol. 2025;24:635-636.
    PubMed    
    
    
    
29. CHENG Y, Zhang Y, Zhang S, Shang H, et al
    Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease.
    Lancet Neurol. 2025;24:634.
    PubMed    
    
    
    
30. WALSH S, Howard R, Richard E, Milne R, et al
    Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease.
    Lancet Neurol. 2025;24:634.
    PubMed    
    
    
    July 2025
31. TEUNISSEN C, Duits F
    Plasma biomarkers for diagnosis and prognosis in Down syndrome-related Alzheimer's disease.
    Lancet Neurol. 2025;24:561-562.
    PubMed    
    
    
    June 2025
32. MARINO C, Malotaux V, Giudicessi A, Aguillon D, et al
    Protective genetic variants against Alzheimer's disease.
    Lancet Neurol. 2025;24:524-534.
    PubMed     Abstract available
    
    
    
33. THE LANCET NEUROLOGY
    A genetic framework for Alzheimer's disease prevention.
    Lancet Neurol. 2025;24:471.
    PubMed    
    
    
    May 2025
34. MATAR E, Halliday GM
    Biological effects of pathologies in Lewy body diseases: why timing matters.
    Lancet Neurol. 2025;24:441-455.
    PubMed     Abstract available
    
    
    April 2025
35. BATEMAN RJ, Li Y, McDade EM, Llibre-Guerra JJ, et al
    Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.
    Lancet Neurol. 2025;24:316-330.
    PubMed     Abstract available
    
    
    
36. SCHOTT JM
    Amyloid immunotherapy to prevent Alzheimer's disease: the wrong drug at the right time?
    Lancet Neurol. 2025;24:279-281.
    PubMed    
    
    
    February 2025
37. BLANQUIE O, Guizzaro L, Herold R, Haberkamp M, et al
    EU regulatory horizons for Alzheimer's disease.
    Lancet Neurol. 2025;24:96-97.
    PubMed    
    
    
    
38. MASTERS CL
    Should the preclinical stage of Alzheimer's disease be disclosed?
    Lancet Neurol. 2025;24:94-95.
    PubMed    
    
    
    January 2025
39. THE LANCET NEUROLOGY
    Bridging the diagnostic gap in Alzheimer's disease.
    Lancet Neurol. 2025;24:1.
    PubMed    
    
    
    December 2024
40. SCHWORER EK, Zammit MD, Wang J, Handen BL, et al
    Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.
    Lancet Neurol. 2024;23:1214-1224.
    PubMed     Abstract available
    
    
    
41. HUNDAL H
    Frank Longo: taking on Alzheimer's disease.
    Lancet Neurol. 2024;23:1188.
    PubMed    
    
    
    
42. RAFII MS
    The amyloid clock: mapping Alzheimer's disease in Down syndrome.
    Lancet Neurol. 2024;23:1173-1174.
    PubMed    
    
    
    October 2024
43. STIRRUPS R
    Navigating the roads ahead for Alzheimer's disease.
    Lancet Neurol. 2024;23:971.
    PubMed    
    
    
    
44. HYMAN BT
    Amyloid removal and the appearance of brain volume loss.
    Lancet Neurol. 2024;23:957-958.
    PubMed    
    
    
    
45. BELDER CRS, Boche D, Nicoll JAR, Jaunmuktane Z, et al
    Brain volume change following anti-amyloid beta immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy.
    Lancet Neurol. 2024;23:1025-1034.
    PubMed     Abstract available
    
    
    September 2024
46. THE LANCET NEUROLOGY
    The evolving paradigm of Alzheimer's disease diagnosis.
    Lancet Neurol. 2024;23:845.
    PubMed    
    
    
    August 2024
47. OHRY A
    Ezio Giacobini: a leader in Alzheimer's disease research.
    Lancet Neurol. 2024;23:768.
    PubMed    
    
    
    July 2024
48. SCHULTZ SA, Liu L, Schultz AP, Fitzpatrick CD, et al
    gamma-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00236.
    PubMed     Abstract available
    
    
    
49. POTIER MC, Steiner H, Chavez-Gutierrez L
    Amyloid beta, gamma-secretase, and familial Alzheimer's disease.
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00292.
    PubMed    
    
    
    June 2024
50. KAPASI A, Schneider JA
    Speculation on the transmissibility of Alzheimer's disease.
    Lancet Neurol. 2024;23:555-556.
    PubMed    
    
    
    May 2024
51. WISCH JK, McKay NS, Boerwinkle AH, Kennedy J, et al
    Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2024;23:500-510.
    PubMed     Abstract available
    
    
    
52. NORDBERG A
    Insights into the progression of genetic Alzheimer's disease from tau PET.
    Lancet Neurol. 2024;23:453-454.
    PubMed    
    
    
    March 2024
53. FRISONI GB, Festari C, Massa F, Cotta Ramusino M, et al
    European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders.
    Lancet Neurol. 2024;23:302-312.
    PubMed     Abstract available
    
    
    
54. THE LANCET NEUROLOGY
    Dementia diagnosis in the anti-amyloid era.
    Lancet Neurol. 2024;23:219.
    PubMed    
    
    
    February 2024
55. CHAPLEAU M, La Joie R, Yong K, Agosta F, et al
    Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
    Lancet Neurol. 2024;23:168-177.
    PubMed     Abstract available
    
    
    
56. REIMAN EM, Cummings JL, Langbaum JB, Mattke S, et al
    A chance to prevent Alzheimer's disease sooner than you think.
    Lancet Neurol. 2024;23:144-145.
    PubMed    
    
    
    
57. BEJANIN A, Villain N
    Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease.
    Lancet Neurol. 2024;23:127-128.
    PubMed    
    
    
    January 2024
58. DELRIEU J, Andrieu S, Vellas B
    Dementia research in 2023: the year of anti-amyloid immunotherapy.
    Lancet Neurol. 2024;23:13-15.
    PubMed    
    
    
    December 2023
59. RANSCOMBE P
    Powerful series profiles rare forms of dementia.
    Lancet Neurol. 2023;22:1112.
    PubMed    
    
    
    November 2023
60. SCHLEPCKOW K, Morenas-Rodriguez E, Hong S, Haass C, et al
    Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease.
    Lancet Neurol. 2023;22:1048-1060.
    PubMed     Abstract available
    
    
    September 2023
61. JAGUST WJ, Teunissen CE, DeCarli C
    The complex pathway between amyloid beta and cognition: implications for therapy.
    Lancet Neurol. 2023;22:847-857.
    PubMed     Abstract available
    
    
    July 2023
62. BELDER CRS, Schott JM, Fox NC
    Preparing for disease-modifying therapies in Alzheimer's disease.
    Lancet Neurol. 2023 Jul 14:S1474-4422(23)00274.
    PubMed    
    
    
    
63. FRISONI GB
    Complexity is the simple truth about Alzheimer's disease.
    Lancet Neurol. 2023 Jul 13:S1474-4422(23)00176.
    PubMed    
    
    
    June 2023
64. THE LANCET NEUROLOGY
    Treatment for Alzheimer's disease: time to get ready.
    Lancet Neurol. 2023;22:455.
    PubMed    
    
    
    
65. MASON M, Bacioglu M, Vivacqua G, Spillantini MG, et al
    Targeting tau degradation: a viable therapeutic approach?
    Lancet Neurol. 2023;22:462-464.
    PubMed    
    
    
    May 2023
66. LANGWORTH-GREEN C, Patel S, Jaunmuktane Z, Jabbari E, et al
    Chronic effects of inflammation on tauopathies.
    Lancet Neurol. 2023;22:430-442.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum